Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Matrix Metalloproteinases in Atherosclerosis of Chronic Kidney Disease (MMACKD)

The recruitment status of this study is unknown because the information has not been verified recently.
Verified September 2011 by Aristotle University Of Thessaloniki.
Recruitment status was  Not yet recruiting
Sponsor:
Collaborator:
AHEPA University Hospital
Information provided by (Responsible Party):
Grigorios G. DIMAS, Aristotle University Of Thessaloniki
ClinicalTrials.gov Identifier:
NCT01458158
First received: September 30, 2011
Last updated: October 21, 2011
Last verified: September 2011
  Purpose

The purpose of this study is to determine whether matrix metalloproteinases are associated with atherosclerosis in the different stages of chronic kidney disease.


Condition
Diabetic Nephropathy

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Cross-Sectional
Official Title: The Role of Matrix Metalloproteinases -2 and -9 in Atherosclerosis of Patients With Chronic Kidney Disease

Resource links provided by NLM:


Further study details as provided by Aristotle University Of Thessaloniki:

Primary Outcome Measures:
  • Association of matrix metalloproteinases with atherosclerosis in patients with chronic kidney disease [ Time Frame: two years ] [ Designated as safety issue: No ]
    Matrix metalloproteinases associated with atherosclerosis in chronic kidney disease;patients with diabetes mellitus type 2 and others with chronic glomerulonephritis.Serum levels of MMPs-2 and -9 are measured by an ELISA system.Intima Media Thickness(IMT) of carotid and femoral arteries is measured with a high resolution ultrasonography.


Secondary Outcome Measures:
  • Matrix metalloproteinases and atherosclerosis associated with pro-inflammatory and oxidative stress markers in chronic kidney disease [ Time Frame: two years ] [ Designated as safety issue: No ]
    Matrix metalloproteinases associated with atherosclerosis markers,pro-inflammatory markers and markers of oxidative stress in chronic kidney disease


Biospecimen Retention:   Samples Without DNA

serum and vessels


Estimated Enrollment: 300
Study Start Date: October 2011
Estimated Study Completion Date: May 2014
Estimated Primary Completion Date: May 2012 (Final data collection date for primary outcome measure)
Groups/Cohorts
Diabetic nephropathy
Diabetic nephropathy in patients with type 2 diabetes
chronic glomerulonephritis
chronic glomerulonephritis in patients without diabetes mellitus
controls
participants without diabetic nephropathy and chronic glomerulonephritis

Detailed Description:

The purpose of this study is to determine the correlation of matrix metalloproteinases and atherosclerosis of chronic kidney disease. Patients with diabetes mellitus type 2,as a non-inflammatory leading cause of end stage renal failure and patients with chronic glomerulonephritis and similar course of proteinuria,as an inflammatory leading cause of end stage renal failure are enrolled.

  Eligibility

Ages Eligible for Study:   50 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population

Patients from University Hospital AHEPA

Criteria

Inclusion Criteria:

  • Chronic kidney disease
  • Diabetes mellitus type 2

Exclusion Criteria:

  • Malignancy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01458158

Contacts
Contact: Grigorios G. Dimas +0030 6972321534 gregorydimas@yahoo.gr

Locations
Greece
AHEPA University Hospital, Medical School of Aristotle University of Thessaloniki
Thessaloniki, Greece
Sponsors and Collaborators
Aristotle University Of Thessaloniki
AHEPA University Hospital
Investigators
Principal Investigator: Grigorios G. Dimas, MD AHEPA University Hospital,Medical School of Aristotle University of Thessaloniki
  More Information

No publications provided

Responsible Party: Grigorios G. DIMAS, Doctor/PhD Candidate, Aristotle University Of Thessaloniki
ClinicalTrials.gov Identifier: NCT01458158     History of Changes
Other Study ID Numbers: A13749, 31-8-2010
Study First Received: September 30, 2011
Last Updated: October 21, 2011
Health Authority: Greece: Ethics Committee

Keywords provided by Aristotle University Of Thessaloniki:
Gelatinases
kidney disease
diabetes mellitus type 2

Additional relevant MeSH terms:
Arteriosclerosis
Atherosclerosis
Diabetic Nephropathies
Kidney Diseases
Renal Insufficiency, Chronic
Arterial Occlusive Diseases
Cardiovascular Diseases
Diabetes Complications
Diabetes Mellitus
Endocrine System Diseases
Renal Insufficiency
Urologic Diseases
Vascular Diseases

ClinicalTrials.gov processed this record on November 25, 2014